Filter
Period
Filter by
recent search
Showing: 1 – 05 of 152 Regulated Information
–
09 February 2023
09 February 2023
LinkedIn
Facebook
Ipsen presents strong full-year 2022 results and guidance for 2023
Paris (France), 9 February 2023
–
09 January 2023
09 January 2023
LinkedIn
Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases
PARIS, FRANCE & BOSTON, U.S., 09 January 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) and Albireo (Nasdaq: ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators…
–
06 January 2023
06 January 2023
LinkedIn
Ipsen – Half year statement – 2022 12 31
This article or press release has no online content. Please download the associated documents for more information.
–
06 January 2023
06 January 2023
LinkedIn
Voting rights on 31 December 2022
This article or press release has no online content. Please download the associated documents for more information.
–
14 December 2022
14 December 2022
LinkedIn
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
PARIS, FRANCE, 23 December 2022 – The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for palovarotene, an investigational treatment for the reduction of new abnormal bone formation (heterotopic ossification) in people…